You are here

Chitosan Endoluminal Hemostatic Dressing

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42DK078400-02A1
Agency Tracking Number: R42DK078400
Amount: $892,569.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 400
Solicitation Number: PA13-235
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-20
Award End Date (Contract End Date): 2016-08-31
Small Business Information
720 SW WASHINGTON ST, STE 200, Portland, OR, 97205-3504
DUNS: 116661344
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 SIMON MCCARTHY
 (503) 245-0459
 simonm@hemcon.com
Business Contact
 MICHELLE SELLS
Phone: (971) 223-4905
Email: msells@hemcon.com
Research Institution
 OREGON HEALTH & SCIENCE UNIVERSITY
 3181 SW Sam Jackson Pk Rd
PORTLAND, OR, 97239-3098
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Perioperative hemorrhage remains the major complication of transurethral and open prostatic surgical procedures Significant blood loss from these procedures causes delayed healing and longer hospitalization which significantly increases the cost of patient care Moreover prolonged urethral catheterization due to significant post operative hematuria is one of the major causes of discomfort and increases the morbidity to the patients after prostatic surgery Our goal is to develop a novel chitosan endoluminal hemostatic dressing CEHD that is able to be delivered by a catheter to control and prevent prostatic bleeding via transurethral application enabling significant reduction in catheter indwelling time and providing for reduced length of hospital stay following prostatic surgery In our Phase I study we successfully demonstrated development of a safe and effective hemostatic chitosan CEHD for transurethral delivery incorporation of the CEHD as part of a urinary catheter device determination of transurethral operational procedures and protocols in deployment of the CEHD and demonstration of the feasibility of CEHD for hemorrhage control via transurethral application in a swine bladder neck injury model The Phase I study results demonstrated significant control of bleeding from bladder neck injury in the first hours with lower red cell counts in urine after the CEHD device deployment compared to controls in the in vivo model In the Phase II application through systematic final prototype improvements we propose to finalize the CEHD design and complete pre clinical efficacy and safety studies in support of an IDE application The proposed Phase II study includes modifications to the CEHD to enhance tissue adhesion and material dissolution finalization of the the CEHD to provide for manufacturability demonstration of ease of CEHD delivery demonstration of safety and efficacy in vivo PUBLIC HEALTH RELEVANCE The CEHD development will rapidly control bleeding and enable reduction in hospital days required for observation following prostatectomy As well as reducing discomfort associated with extended catheterization the CEHD development has the potential to significantly reduce the overall cost of hospitalization associated with bleeding following prostatectomy by hundreds of millions of dollars This development will reduce prostatectomy related morbidity and assist with reduction in mortality

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government